Search
tenapanor (Ibsrela)
Indications:
- irritable bowel syndrome with constipation
- control of serum phosphorus levels in adults with chronic kidney disease on dialysis, as a single agent or in combination with phosphate binder
Dosage:
- 50 mg PO BID (immediately before breakfast & immediately before dinner)
Tabs: 50 mg
Adverse effects:
- diarrhea
Mechanism of action:
- inhibits sodium-hydrogen exchanger NHE3 in the GI tract
General
gastrointestinal agent
metabolic agent (metabolic modifier)
Database Correlations
PUBCHEM cid=71587953
References
- RxNorm
- Brooks M
FDA OKs Tenapanor (Ibsrela) for IBS With Constipation in Adult
Medscape - Sep 12, 2019.
https://www.medscape.com/viewarticle/918341
- Wikipedia: Tenapanor
https://en.wikipedia.org/wiki/Tenapanor
- Kuznar W
FDA Panel Endorses Kidney Disease Drug for Serum Phosphorus Control.
Advisors see need for alternatives, citing suboptimal efficacy and
tolerance of approved options.
MedPage Today. November 17, 2022
https://www.medpagetoday.com/nephrology/generalnephrology/101802
- Lembo AJ, Chey WD, Harris LA et al.
Abdominal Symptom Improvement During Clinical Trials of Tenapanor in Patients
With Irritable Bowel Syndrome With Constipation: A Post Hoc Analysis.
Am J Gastroenterol. 2024 Mar 15
PMID: 38294158
https://journals.lww.com/ajg/fulltext/9900/abdominal_symptom_improvement_during_clinical.1000.aspx